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Background: Over half of heart failure (HF) patients with an implantable cardioverter-defibrillator (ICD) placed for the prevention of sudden 
cardiac death (SCD) never require an ICD shock based on current risk stratification guidelines. We previously found that HF patients have increased 
levels of alternatively spliced voltage gated sodium channel (SCN5A) mRNA variants which lead to truncated and non functional channels and could 
increase arrhythmic risk. The same splicing is also found in peripheral lymphocytes. In this study, we compared levels of SCN5A splicing variants in 
lymphocytes of HF patients who received appropriate ICD shock and in those who received no shock.
Methods: In this cross sectional study, we enrolled HF patients with a left ventricular ejection fraction ≤ 35% with an ICD for SCD prevention. 
Patients with congenital heart disease, active infections and inflammatory conditions were excluded. Patients were divided into 2 groups, those who 
had received appropriate ICD intervention for sustained VT or VF (n=45) and those who had not (n=45). Lymphocyte SCN5A splice variants were 
measured by RT-PCR from a single blood draw.
Results: There were no significant differences between the two groups in age, race, gender, New York Heart Association Class, presence of coronary 
disease, QRS duration and ACE inhibitor and anti-arrhythmic drug use. Controlling for these factors, HF patients who had received appropriate 
intervention had higher levels of SCN5A splice variants compared to those who had not, OR= 3.25 (95% CI 1.64-6.45) (p= .001). The area under the 
receiver operating characteristic curve for the splice variant levels was 0.96, suggesting that this test had a high accuracy.
Conclusions: HF patients who had received appropriate ICD intervention had significantly higher levels of SCN5A splice variants compared 
to patients who had not received an appropriate intervention. These patients will be followed prospectively to confirm if a blood test measuring 
lymphocyte SCN5A splice variant levels could be used as a marker for predicting SCD risk in HF.
